Literature DB >> 8071518

Is omeprazole helpful in inflammatory bowel disease?

J B Dickinson1.   

Abstract

Omeprazole, a proton pump inhibitor, was added to the treatment regimen of seven patients with biopsy proven inflammatory bowel disease. Six of the seven patients showed a marked clinical improvement in symptoms, especially pain and diarrhea after starting omeprazole. One of the six is using omeprazole as her sole medication for her colitis currently. Others have been able to decrease steroid doses. A possible mechanism of action relates the similar chemical structure of omeprazole to metronidazole which is efficacious in colitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071518     DOI: 10.1097/00004836-199406000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Management of difficult inflammatory bowel disease: where are we now?

Authors:  DS Rampton
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Suppression of proinflammatory cytokine production in macrophages by lansoprazole.

Authors:  Akinari Hinoki; Kazunori Yoshimura; Keiko Fujita; Masumi Akita; Rie Ikeda; Masabumi Nagashima; Masahiko Nomura; Akira Satomi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

3.  Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.

Authors:  B Dave; W Rubin
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

4.  Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.

Authors:  Masahiko Nakamura; Maki Asada; Koichiro Atsuda; Hidenori Matsui; Toshio Watanabe; Kazuhide Higuchi; Tetsuo Arakawa; Norifumi Hibi; Kanji Tsuchimoto
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Lansoprazole inhibits nitric oxide and prostaglandin E(2) production in murine macrophage RAW 264.7 cells.

Authors:  Shuji Nakagawa; Yuji Arai; Tsunao Kishida; Nobuyuki Hiraoka; Shinji Tsuchida; Hiroaki Inoue; Ryo Sakai; Osam Mazda; Toshikazu Kubo
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 6.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.